Exelixis vs United Therapeutics
Exelixis (EXEL) and United Therapeutics (UTHR) side by side: how big they are, what they earn, how their shares have moved and what insiders, members of Congress and funds reported. Figures from filings and closing prices; none of this is a view on either stock.
- Market value
- $15.8B
- Last close
- $64.63
- 12 months
- +54.7%
- Market value
- $23.6B
- Last close
- $554.73
- 12 months
- +16.9%
At a glance
- The biggest part of Exelixis's revenue is CABOMETYX (91%); at United Therapeutics it is Tyvaso DPI (41%).
- By market value, United Therapeutics ($23.6B) is about 1.5 times Exelixis ($15.8B).
- Over the last 12 months Exelixis's share price moved +54.7% and United Therapeutics's +16.9%; against the S&P 500 that is +49.0 points and +11.1 points.
- In their last fiscal years Exelixis kept 33.7% of revenue as net income and United Therapeutics 41.9%.
- In the last 90 days insiders reported 0 open-market purchases at Exelixis and 0 at United Therapeutics; members of Congress disclosed 0 trades in Exelixis and 0 in United Therapeutics.
- Next results: Exelixis Feb 8, 2027, United Therapeutics Feb 23, 2027.
How each one makes money: Exelixis revenue · United Therapeutics revenue
Share prices on one chart
Exelixis and United Therapeutics, and up to three more you add, drawn on the same scale so you can see which moved more.
Face to face
The figures that separate the two, drawn to the same scale. Every figure is also in the table below.
Size
Market value
Revenue, last fiscal year
Net income, last fiscal year
Every figure
| Exelixis EXELNASDAQ · Biotechnology | United Therapeutics UTHRNASDAQ · Biotechnology | |
|---|---|---|
| Size and profitability | ||
| Market value | $15.8B | $23.6B |
| Revenue, last fiscal year | $2.32B | $3.18B |
| Net income, last fiscal year | $783M | $1.33B |
| Net marginNet income as a share of revenue | 33.7% | 41.9% |
| Free cash flow | $876M | |
Prices are end-of-day closes, and fundamentals are the companies' last annual figures from their SEC filings: a − or + in the table is a fact of the filing or the close, not a forecast. Market value is the company-level figure at the last close. Counts are of records OQRO holds, by their date; insider history since 2006 comes from the SEC's insider transactions data sets and every filing since. Planned sales under a 10b5-1 plan are counted like other sales.
Common questions
How is Exelixis different from United Therapeutics?
Exelixis (EXEL) is in Biotechnology on NASDAQ, with $2.32B of revenue in its last fiscal year and a net margin of 33.7%. United Therapeutics (UTHR) is in Biotechnology on NASDAQ, with $3.18B of revenue in its last fiscal year and a net margin of 41.9%. The biggest part of Exelixis's revenue is CABOMETYX (91%); at United Therapeutics it is Tyvaso DPI (41%). The table above sets their figures side by side; it compares filings and is not a view on either stock.
How do Exelixis and United Therapeutics compare in size?
United Therapeutics has the larger market value: Exelixis $15.8B and United Therapeutics $23.6B, at the last close.
Whose share price rose more over the last 12 months, EXEL or UTHR?
Over the last 12 months Exelixis moved +54.7% and United Therapeutics +16.9%. Past price moves say nothing about the future.
Which has had more insider buying, Exelixis or United Therapeutics?
Since 2006, Exelixis insiders reported 114 open-market purchases against 43 for United Therapeutics. These are counts of what was filed, not a view on either stock.
Do members of Congress trade EXEL or UTHR?
In the last 12 months, members of Congress disclosed 0 trades in Exelixis (EXEL) and 0 in United Therapeutics (UTHR).
When did insiders last buy EXEL and UTHR?
See the record behind any of these
A free account opens the full history of every insider and company since 2006, the screener, alerts, Congress trades and fund moves.
Exelixis pageUnited Therapeutics pageRare insider trades this weekAll comparisons
https://oqro.io/compare/exel-vs-uthr

